Shire wins FDA approval for new ADHD drug

The FDA has approved a Shire plc drug for ADHD that has the same active ingredient as an extended-release version of Adderall but is designed to last longer than the popular generic. The drug, which will be sold under the brand name "Mydayis," is designed to last for 16 hours, compared with 12 hours for Adderall XR, which was also developed by Shire (Nasdaq: SHPG). That means it could be taken just once a day by people 13 years and older with ADHD. The disorder affects about 4 percent of adults…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news